Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naive Hodgkin lymphoma, Stage IIa or IIb-IV~* Measurable disease of at least 1.5 cm~* Eastern Cooperative Oncology Group performance status \<3~Exclusion Criteria:~* History of another primary malignancy that has not been in remission for at least 3 years~* Known cerebral/meningeal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): brentuximab vedotin combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
- 2 (Type: EXPERIMENTAL): brentuximab vedotin combined with AVD (doxorubicin, vinblastine, dacarbazine)

Based on this trial design, predict the completion outcome and termination type (if applicable).